Search

Your search keyword '"Janus, Cecile"' showing total 116 results
Start Over Author "Janus, Cecile"
116 results on '"Janus, Cecile"'

2. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma

Author

Opstal-van Winden, Annemieke W.J., de Haan, Hugoline G., Hauptmann, Michael, Schmidt, Marjanka K., Broeks, Annegien, Russell, Nicola S., Janus, Cécile P.M., Krol, Augustinus D.G., van der Baan, Frederieke H., De Bruin, Marie L., van Eggermond, Anna M., Dennis, Joe, Anton-Culver, Hoda, Haiman, Christopher A., Sawyer, Elinor J., Cox, Angela, Devilee, Peter, Hooning, Maartje J., Peto, Julian, Couch, Fergus J., Pharoah, Paul, Orr, Nick, Easton, Douglas F., Aleman, Berthe M.P., Strong, Louise C., Bhatia, Smita, Cooke, Rosie, Robison, Leslie L., Swerdlow, Anthony J., and van Leeuwen, Flora E.

Published
2019
Full Text
View/download PDF

3. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, primary, Krul, Inge M., additional, Schaapveld, Michael, additional, Janus, Cecile P. M., additional, Rademakers, Saskia E., additional, Roesink, Judith M., additional, Nijziel, Marten R., additional, Bilgin, Yavuz M., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional

Published
2023
Full Text
View/download PDF

5. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

8. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

9. Risk of male breast cancer after Hodgkin lymphoma

Author

van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Published
2023
Full Text
View/download PDF

10. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., Lansdorp-Vogelaar, Iris, Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 mg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 mg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 mg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 mg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was

Published
2022

11. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Abstract

Background: Hodgkin’s lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right-sided, were detected, as published previously. An average-risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. Results: In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high-grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4–9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Conclusions: Colorectal neoplasia in HL survivors differ from average-risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow-up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors.

Published
2022

12. Cost-effectiveness of colorectal cancer surveillance in Hodgkin lymphoma survivors treated with procarbazine and/or infradiaphragmatic radiotherapy

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, Lansdorp-Vogelaar, Iris, MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, and Lansdorp-Vogelaar, Iris

Published
2022

13. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Published
2022

15. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.

Author

Ykema, Berbel L. M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H. M., Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Aleman, Berthe M. P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 µg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 µg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 µg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 µg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was the most cost-effective strategy. Impact: Colorectal cancer surveillance should be implemented in Hodgkin lymphoma survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts

Author

Moskowitz, Chaya S., primary, Ronckers, Cécile M., additional, Chou, Joanne F., additional, Smith, Susan A., additional, Friedman, Danielle Novetsky, additional, Barnea, Dana, additional, Kok, Judith L., additional, de Vries, Simone, additional, Wolden, Suzanne L., additional, Henderson, Tara O., additional, van der Pal, Helena J. H., additional, Kremer, Leontien C. M., additional, Neglia, Joseph P., additional, Turcotte, Lucie M., additional, Howell, Rebecca M., additional, Arnold, Michael A., additional, Schaapveld, Michael, additional, Aleman, Berthe, additional, Janus, Cecile, additional, Versluys, Birgitta, additional, Leisenring, Wendy, additional, Sklar, Charles A., additional, Begg, Colin B., additional, Pike, Malcolm C., additional, Armstrong, Gregory T., additional, Robison, Leslie L., additional, van Leeuwen, Flora E., additional, and Oeffinger, Kevin C., additional

Published
2021
Full Text
View/download PDF

17. On the Importance of Individualized, Non-Coplanar Beam Configurations in Mediastinal Lymphoma Radiotherapy, Optimized With Automated Planning

Author

Rossi, Linda, Cambraia Lopes Ferreira Da Silva, Patrícia, Marques Leitáo, Joana, Janus, Cecile, van de Pol, Marjan, Breedveld, Sebastiaan, Penninkhof, Joan, Heijmen, Ben J.M., Rossi, Linda, Cambraia Lopes Ferreira Da Silva, Patrícia, Marques Leitáo, Joana, Janus, Cecile, van de Pol, Marjan, Breedveld, Sebastiaan, Penninkhof, Joan, and Heijmen, Ben J.M.

Abstract

Background and purpose: Literature is non-conclusive regarding selection of beam configurations in radiotherapy for mediastinal lymphoma (ML) radiotherapy, and published studies are based on manual planning with its inherent limitations. In this study, coplanar and non-coplanar beam configurations were systematically compared, using a large number of automatically generated plans. Material and methods: An autoplanning workflow, including beam configuration optimization, was configured for young female ML patients. For each of 25 patients, 24 plans with different beam configurations were generated with autoplanning: 11 coplanar CP_x plans and 11 non-coplanar NCP_x plans with x = 5 to 15 IMRT beams with computer-optimized, patient-specific configurations, and the coplanar VMAT and non-coplanar Butterfly VMAT (B-VMAT) beam angle class solutions (600 plans in total). Results: Autoplans compared favorably with manually generated, clinically delivered plans, ensuring that beam configuration comparisons were performed with high quality plans. There was no beam configuration approach that was best for all patients and all plan parameters. Overall there was a clear tendency towards higher plan quality with non-coplanar configurations (NCP_x≥12 and B-VMAT). NCP_x≥12 produced highly conformal plans with on average reduced high doses in lungs and patient and also a reduced heart Dmean, while B-VMAT resulted in reduced low-dose spread in lungs and left breast. Conclusions: Non-coplanar beam configurations were favorable for young female mediastinal lymphoma patients, with patient-specific and plan-parameter-dependent dosimetric advantages of NCP_x≥12 and B-VMAT. Individualization of beam configuration approach, considering also the faster delivery of B-VMAT vs. NCP_x≥12, can importantly improve the treatments.

Published
2021

18. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

Ykema, Berbel L. M., primary, Rigter, Lisanne S., additional, Spaander, Manon C. W., additional, Moons, Leon M. G., additional, Bisseling, Tanya M., additional, Aleman, Berthe M. P., additional, Dekker, Evelien, additional, Verbeek, Wieke H. M., additional, Kuipers, Ernst J., additional, Boer, Jan Paul, additional, Lugtenburg, Pieternella J., additional, Janus, Cecile P. M., additional, Petersen, Eefke J., additional, Roesink, Judith M., additional, Maazen, Richard W. M., additional, Meijer, Gerrit A., additional, Schaapveld, Michael, additional, Leeuwen, Flora E., additional, Carvalho, Beatriz, additional, Snaebjornsson, Petur, additional, and Leerdam, Monique E., additional

Published
2021
Full Text
View/download PDF

19. Anthracycline exposure and breast cancer risk in female Hodgkin lymphoma survivors.

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M., additional, Aleman, Berthe M.P., additional, Janus, Cecile P.M., additional, Rademakers, Saskia E, additional, de Weijer, Roel J., additional, Van Der Maazen, Richard W.M., additional, Zijlstra, Josée M., additional, Beijert, Max, additional, Verschueren, Karijn M.S., additional, Ta, Bastiaan, additional, Nijziel, Marten R., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Muller, Karin, additional, te Boome, Liane, additional, Bilgin, Yavuz, additional, de Jongh, Eva, additional, Schaapveld, Michael, additional, and Van Leeuwen, Flora, additional

Published
2021
Full Text
View/download PDF

21. Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors

Author

Ykema, Berbel, Rigter, Lisanne, Spaander, Manon, Moons, Leon, Bisseling, Tanya, Aleman, Berthe, de Boer, Jan Paul, Lugtenburg, Pieternella, Janus, Cecile, Petersen, Eefke, Roesink, Judith, Raemaekers, John, van der Maazen, Richard, Lansdorp-Vogelaar, Iris, Gini, Andrea, Verbeek, Wieke, Lemmens, Margriet, Meijer, Gerrit, van Leeuwen, Flora, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique, Ykema, Berbel, Rigter, Lisanne, Spaander, Manon, Moons, Leon, Bisseling, Tanya, Aleman, Berthe, de Boer, Jan Paul, Lugtenburg, Pieternella, Janus, Cecile, Petersen, Eefke, Roesink, Judith, Raemaekers, John, van der Maazen, Richard, Lansdorp-Vogelaar, Iris, Gini, Andrea, Verbeek, Wieke, Lemmens, Margriet, Meijer, Gerrit, van Leeuwen, Flora, Snaebjornsson, Petur, Carvalho, Beatriz, and van Leerdam, Monique

Published
2020

22. Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Ykema, Berbel, Rigter, Lisanne, Spaander, Manon, Moons, Leon, Bisseling, Tanya, Aleman, Berthe, de Boer, Jan Paul, Lugtenburg, Pieternella, Janus, Cecile, Petersen, Eefke, Roesink, Judith, Raemaekers, John, van der Maazen, Richard, Lansdorp-Vogelaar, Iris, Gini, Andrea, Verbeek, Wieke, Lemmens, Margriet, Meijer, Gerrit, van Leeuwen, Flora, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique, MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Ykema, Berbel, Rigter, Lisanne, Spaander, Manon, Moons, Leon, Bisseling, Tanya, Aleman, Berthe, de Boer, Jan Paul, Lugtenburg, Pieternella, Janus, Cecile, Petersen, Eefke, Roesink, Judith, Raemaekers, John, van der Maazen, Richard, Lansdorp-Vogelaar, Iris, Gini, Andrea, Verbeek, Wieke, Lemmens, Margriet, Meijer, Gerrit, van Leeuwen, Flora, Snaebjornsson, Petur, Carvalho, Beatriz, and van Leerdam, Monique

Published
2020

23. Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors

Author

Ykema, Berbel, primary, Rigter, Lisanne, additional, Spaander, Manon, additional, Moons, Leon, additional, Bisseling, Tanya, additional, Aleman, Berthe, additional, de Boer, Jan Paul, additional, Lugtenburg, Pieternella, additional, Janus, Cecile, additional, Petersen, Eefke, additional, Roesink, Judith, additional, Raemaekers, John, additional, van der Maazen, Richard, additional, Lansdorp-Vogelaar, Iris, additional, Gini, Andrea, additional, Verbeek, Wieke, additional, Lemmens, Margriet, additional, Meijer, Gerrit, additional, van Leeuwen, Flora, additional, Snaebjornsson, Petur, additional, Carvalho, Beatriz, additional, and van Leerdam, Monique, additional

Published
2020
Full Text
View/download PDF

24. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors.

Author

Ykema, Berbel L. M., Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., Aleman, Berthe M. P., Dekker, Evelien, Verbeek, Wieke H. M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, and Snaebjornsson, Petur

Subjects
HODGKIN'S disease, ADENOMATOUS polyps, TUMORS, LOGISTIC regression analysis, CLINICAL pathology, DNA mismatch repair, BREAST cancer prognosis, PROGRESSION-free survival
Abstract

Background: Hodgkin's lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right‐sided, were detected, as published previously. An average‐risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. Results: In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high‐grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4–9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Conclusions: Colorectal neoplasia in HL survivors differ from average‐risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow‐up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Author

Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., van Leerdam, Monique E., Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

26. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors

Author

Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., van Leerdam, Monique E., Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

27. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Author

Cancer, MS Radiotherapie, Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., van Leerdam, Monique E., Cancer, MS Radiotherapie, Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M.P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M.P., van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

28. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors

Author

MS MDL 1, Circulatory Health, MS Radiotherapie, Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., van Leerdam, Monique E., MS MDL 1, Circulatory Health, MS Radiotherapie, Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

29. High Prevalence of Advanced Colorectal Neoplasia and Serrated Polyposis Syndrome in Hodgkin Lymphoma Survivors

Author

Rigter, LS, Spaander, Manon, Aleman, BMP, Bisseling, TM, Moons, LM, Cats, A, Lugtenburg, Elly, Janus, Cecile, Petersen, EJ, Roesink, JM, van der Maazen, RWM, Snaebjornsson, P, Kuipers, Ernst, Bruno, Marco, Dekker, E, Meijer, GA, de Boer, JP, van Leeuwen, FE, Leerdam, ME, Rigter, LS, Spaander, Manon, Aleman, BMP, Bisseling, TM, Moons, LM, Cats, A, Lugtenburg, Elly, Janus, Cecile, Petersen, EJ, Roesink, JM, van der Maazen, RWM, Snaebjornsson, P, Kuipers, Ernst, Bruno, Marco, Dekker, E, Meijer, GA, de Boer, JP, van Leeuwen, FE, and Leerdam, ME

Published
2019

30. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Author

Rigter, LS, Schaapveld, M, Janus, Cecile, Krol, ADG, van der Maazen, RWM, Roesink, J, Zijlstra, JM, van Imhoff, GW, Poortmans, PMP, Beijert, M, Lugtenburg, Elly, Visser, O, Snaebjornsson, P, van Eggermond, AM, Aleman, BMP, van Leeuwen, FE, Leerdam, ME, Rigter, LS, Schaapveld, M, Janus, Cecile, Krol, ADG, van der Maazen, RWM, Roesink, J, Zijlstra, JM, van Imhoff, GW, Poortmans, PMP, Beijert, M, Lugtenburg, Elly, Visser, O, Snaebjornsson, P, van Eggermond, AM, Aleman, BMP, van Leeuwen, FE, and Leerdam, ME

Published
2019

31. Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Author

Rigter, Lisanne S., primary, Schaapveld, Michael, additional, Janus, Cecile P. M., additional, Krol, Augustinus D. G., additional, van der Maazen, Richard W. M., additional, Roesink, Judith, additional, Zijlstra, Josee M., additional, van Imhoff, Gustaaf W., additional, Poortmans, Philip M. P., additional, Beijert, Max, additional, Lugtenburg, Pieternella J., additional, Visser, Otto, additional, Snaebjornsson, Petur, additional, van Eggermond, Anna M., additional, Aleman, Berthe M. P., additional, van Leeuwen, Flora E., additional, and van Leerdam, Monique E., additional

Published
2018
Full Text
View/download PDF

32. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors

Author

Rigter, Lisanne S., primary, Spaander, Manon C. W., additional, Aleman, Berthe M. P., additional, Bisseling, Tanya M., additional, Moons, Leon M., additional, Cats, Annemieke, additional, Lugtenburg, Pieternella J., additional, Janus, Cecile P. M., additional, Petersen, Eefke J., additional, Roesink, Judith M., additional, van der Maazen, Richard W. M., additional, Snaebjornsson, Petur, additional, Kuipers, Ernst J., additional, Bruno, Marco J., additional, Dekker, Evelien, additional, Meijer, Gerrit A., additional, de Boer, Jan Paul, additional, van Leeuwen, Flora E., additional, and van Leerdam, Monique E., additional

Published
2018
Full Text
View/download PDF

33. Cardiovascular disease risk after treatment-induced primary ovarian insufficiency in female survivors of Hodgkin lymphoma.

Author

Van Leeuwen, Flora, primary, Krul, Inge, additional, Opstal-Van Winden, Annemieke, additional, Janus, Cecile P.M., additional, Daniels, Laurien, additional, Maas, Angela, additional, Van Nimwegen, Rianne, additional, de Vries, Simone, additional, Hauptmann, Michael, additional, Józwiak, Katarzyna, additional, and Aleman, Berthe M.P., additional

Published
2018
Full Text
View/download PDF

34. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer : study design

Author

Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, van Leerdam, Monique E, Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, and van Leerdam, Monique E

Published
2017

35. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design

Author

MS MDL Oncologie, Cancer, MS MDL 1, Regenerative Medicine and Stem Cells, MS Hematologie, MS Radiotherapie, Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, van Leerdam, Monique E, MS MDL Oncologie, Cancer, MS MDL 1, Regenerative Medicine and Stem Cells, MS Hematologie, MS Radiotherapie, Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, and van Leerdam, Monique E

Published
2017

36. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design

Author

Rigter, LS, Spaander, Manon, Moons, LM, Bisseling, TM, Aleman, BMP, de Boer, JP, Lugtenburg, Elly, Janus, Cecile, Petersen, EJ, Roesink, JM, Raemaekers, JMM, van der Maazen, RWM, Cats, A, Bleiker, EMA, Snaebjornsson, P, Carvalho, B, Lansdorp - Vogelaar, Iris, Jozwiak, K, te Riele, H, Meijer, GA, van Leeuwen, FE, van Leerdam, ME, Rigter, LS, Spaander, Manon, Moons, LM, Bisseling, TM, Aleman, BMP, de Boer, JP, Lugtenburg, Elly, Janus, Cecile, Petersen, EJ, Roesink, JM, Raemaekers, JMM, van der Maazen, RWM, Cats, A, Bleiker, EMA, Snaebjornsson, P, Carvalho, B, Lansdorp - Vogelaar, Iris, Jozwiak, K, te Riele, H, Meijer, GA, van Leeuwen, FE, and van Leerdam, ME

Published
2017

37. Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors

Author

van Eggermond, AM, Schaapveld, M, Janus, Cecile, de Boer, JP, Krol, ADG, Zijlstra, JM, van der Maazen, RWM, Kremer, LC, van Leerdam, ME, Louwman, MWJ, Visser, O, Bruin, ML, Aleman, BMP, van Leeuwen, FE, van Eggermond, AM, Schaapveld, M, Janus, Cecile, de Boer, JP, Krol, ADG, Zijlstra, JM, van der Maazen, RWM, Kremer, LC, van Leerdam, ME, Louwman, MWJ, Visser, O, Bruin, ML, Aleman, BMP, and van Leeuwen, FE

Published
2017

39. The BETER survivorship care initiative for Hodgkin lymphoma; Tailored survivorship care for late effects of treatment

Author

Dekker, Nicky, Van'T Veer, Mars B., Aleman, Berthe M.P., Van Leeuwen, Flora E., Raemaekers, John M.M., Schaapveld, Michael, Opstal-Van Winden, Annemieke, De Boer, Jan Paul, Sombroek, Cherita, Poortmans, Philip, Van Der Maazen, Richard, Lugtenburg, P. J.Elly, Janus, Cecile, Noordijk, Ed, Krol, A. D.G.Stijn, Daniels, Laurien, Zijlstra, Josée, Meijer, Otto, Petersen, Eefke, Buter, Denise, De Weijer, Roel, Roesink, Judith, Kluin-Nelemans, J. C.Hanneke, Van Imhoff, Gustaaf, De Vries, Floriske, Beijert, Max, Kersten, Marie José, Oldenburger, Foppe, Dieleman, Edith, Schouten, Harry, Borger, Jacques, Van De Voorde, Lien, Verschueren, Karijn, Schippers, Maaike, Verbeeten, Bernard, Ong, Francisca, Dorresteijn, Lucille, Schimmel, Erik, Bouma, Paul, Muller, Karin, Lybeert, Marnix, Dompeling, Ellen, Manenschijn, Annelies, Vos-Westerman, J. Hanneke, Van Kampen, Daphne, Dielwart, Michel, Posthuma, Ward, Böhmer, Lara, Te Boome, Liane, Visser, Hein, Epidemiology and Data Science, EMGO - Quality of care, Hematology, CCA - Imaging and biomarkers, CCA - Disease profiling, CCA - Imaging, Radiation Oncology, VU University medical center, and Oral and Maxillofacial Surgery / Oral Pathology

Subjects
humanities
Abstract

The Dutch BETER consortium has established a national care infrastructure for Hodgkin lymphoma survivors. 'BETER' [the Dutch word for 'better'] stands for Better care after Hodgkin lymphoma (HL): Evaluation of longterm Treatment Effects and screening Recommendations. The survivorship care focuses on longterm effects of HL treatment. Over 10,000 HL survivors who were treated in the period spanning 19652008 have been identified. As part of the survivorship care initiative, specific BETER outpatient clinics have been set up. A dedicated website, www.beternahodgkin.nl, provides HL survivors with relevant information. The stakeholders of the BETER survivorship care programme aim to achieve an improved healthy life expectancy for patients treated for HL.

Published
2016

40. Attendance to Hodgkin lymphoma survivorship care clinics in the Netherlands.

Author

Nijdam, Annelies, primary, de Weijer, Roel J., additional, Janus, Cecile P.M., additional, Clevers-Petersen, Eefke J., additional, Roesink, Judith M., additional, Lugtenburg, Pieternella J., additional, van 't Veer, Mars B., additional, Aleman, Berthe M.P., additional, Raemaekers, John M. M., additional, and Van Leeuwen, Flora, additional

Published
2017
Full Text
View/download PDF

41. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design

Author

Rigter, Lisanne S., primary, Spaander, Manon C. W., additional, Moons, Leon M., additional, Bisseling, Tanya M., additional, Aleman, Berthe M. P., additional, de Boer, Jan Paul, additional, Lugtenburg, Pieternella J., additional, Janus, Cecile P. M., additional, Petersen, Eefke J., additional, Roesink, Judith M., additional, Raemaekers, John M. M., additional, van der Maazen, Richard W. M., additional, Cats, Annemieke, additional, Bleiker, Eveline M. A., additional, Snaebjornsson, Petur, additional, Carvalho, Beatriz, additional, Lansdorp-Vogelaar, Iris, additional, Jóźwiak, Katarzyna, additional, te Riele, Hein, additional, Meijer, Gerrit A., additional, van Leeuwen, Flora E., additional, and van Leerdam, Monique E., additional

Published
2017
Full Text
View/download PDF

42. Long-term survival of gastrointestinal cancer diagnosed in Hodgkin lymphoma survivors.

Author

Rigter, Lisanne Sara, primary, Schaapveld, Michael, additional, Aleman, Berthe M.P., additional, Janus, Cecile P.M., additional, van Eggermond, Anna M., additional, Krol, Augustinus D.G., additional, Van Der Maazen, Richard, additional, Roesink, Judith M., additional, Zijlstra, Josee M, additional, Van Imhoff, Gustaaf Willem, additional, Poortmans, Philip M., additional, Beijert, Max, additional, Lugtenburg, Pieternella J., additional, Visser, Otto, additional, Snaebjornsson, Petur, additional, Van Leeuwen, Flora, additional, and van Leerdam, Monique Esther, additional

Published
2017
Full Text
View/download PDF

43. Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma.

Author

Nijdam, Annelies, Dekker, Nicky, Aleman, Berthe M. P., van 't Veer, Mars B., Daniels, Laurien A., Maazen, Richard W., Janus, Cecile P. M., Weijer, Roel J., Zijlstra, Josée M., Stedema, Floriske G., Ta, Bastiaan D., Posthuma, Eduardus F. M., Manenschijn, Annelies, Dielwart, Michel F. H., Bilgin, Yavuz M., Heuvel, Maaike J., Boersma, Rinske S., Leeuwen, Flora E., and Raemaekers, John M. M.

Subjects
HODGKIN'S disease, CANCER patients, ADVERSE health care events, GUIDELINES, MEDICAL care, HEALTH programs
Abstract

The article discusses the creation of a national program for Hodgkin lymphoma (HL) survivorship care in the Netherlands as of August 2019. Topics covered include the steps in screening of late adverse events like cardiovascular disease, thyroid dysfunction, and reduced fertility, the development of guidelines for the most frequent ones, and the flow of data from and to various sources and their use. Also noted are the BETER clinics' coordination with the patients' general practitioners (GP).

Published
2019
Full Text
View/download PDF

44. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Abstract

•Male survivors of HL treated with chest radiotherapy have an increased risk of developing BC compared with the general population.•Although the occurrence of male BC is an uncommon event, clinicians should be alert to BC symptoms in male survivors of HL.

Published
2024
Full Text
View/download PDF

45. Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma

Author

Cutter, DJ, Schaapveld, M, Darby, SC, Hauptmann, M (Michael), van Nimwegen, FA, Krol, ADG, Janus, Cecile, van Leeuwen, FE, Aleman, BMP, Cutter, DJ, Schaapveld, M, Darby, SC, Hauptmann, M (Michael), van Nimwegen, FA, Krol, ADG, Janus, Cecile, van Leeuwen, FE, and Aleman, BMP

Abstract

Background: Hodgkin lymphoma (HL) survivors are at increased risk for developing valvular heart disease (VHD). We evaluated the determinants of the risk and the radiation dose-response. Methods: A case-control study was nested in a cohort of 1852 five-year HL survivors diagnosed at ages 15 to 41 years and treated between 1965 and 1995. Case patients had VHD of at least moderate severity as their first cardiovascular diagnosis following HL treatment. Control patients were matched to case patients for age, gender, and HL diagnosis date. Treatment and follow-up data were abstracted from medical records. Radiation doses to heart valves were estimated by reconstruction of individual treatments on representative computed tomography datasets. All statistical tests were two-sided. Results: Eighty-nine case patients with VHD were identified (66 severe or life-threatening) and 200 control patients. Aortic (n = 63) and mitral valves (n = 42) were most frequently affected. Risks increased more than linearly with radiation dose. For doses to the affected valve(s) of less than or equal to 30, 31-35, 36-40, and more than 40 Gy, VHD rates increased by factors of 1.4, 3.1, 5.4, and 11.8, respectively (P-trend < .001). Approximate 30-year cumulative risks were 3.0%, 6.4%, 9.3%, and 12.4% for the same dose categories. VHD rate increased with splenectomy by a factor of 2.3 (P = .02). Conclusions: Radiation dose to the heart valves can increase the risk for clinically significant VHD, especially at doses above 30 Gy. However, for patients with mediastinal involvement treated today with 20 or 30 Gy, the 30-year risk will be increased by only about 1.4%. These findings may be useful for patients and doctors both before treatment and during follow-up.

Published
2015

48. Risk of Diabetes Mellitus in Long-Term Survivors of Hodgkin Lymphoma

Author

van Nimwegen, Frederika A., primary, Schaapveld, Michael, additional, Janus, Cecile P.M., additional, Krol, Augustinus D.G., additional, Raemaekers, John M.M., additional, Kremer, Leontien C.M., additional, Stovall, Marilyn, additional, Aleman, Berthe M.P., additional, and van Leeuwen, Flora E., additional

Published
2014
Full Text
View/download PDF

50. Cause-specific mortality among patients with Hodgkin lymphoma (HL) up to 40 years after treatment.

Author

Schaapveld, Michael, primary, van Eggermond, Anna M., additional, Janus, Cecile P.M., additional, Krol, Augustinus D.G., additional, Raemaekers, John M. M., additional, Clevers-Petersen, Eefke J., additional, Lugtenburg, Pieternella J., additional, Zijlstra, Jose M., additional, Van Imhoff, Gustaaf Willem, additional, Van Der Maazen, Richard W.M., additional, Roesink, Judith M., additional, Beijert, Max L., additional, Poortmans, Philip M., additional, Kremer, Leontien C.M., additional, Louwman, Marieke J., additional, Lybeert, Marnix, additional, De Boer, J. P., additional, Aleman, Berthe M.P., additional, and van Leeuwen, Flora E., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results